BMC MED:LDL-C达标就不会中风?错!没有进行调脂治疗仍可能有高的卒中风险!

2022-07-10 MedSci原创 MedSci原创

有证据表明,低密度脂蛋白胆固醇(LDL-C)浓度很低的个体发生中风的风险仍然很高。

有证据表明,低密度脂蛋白胆固醇(LDL-C)浓度很低的个体发生中风的风险仍然很高。来自我国的学者试图利用机器学习方法中的生存条件推理树,对LDL-C浓度<70 mg/dL(3.85mmol/L)的中国参与者的中风预测性风险因素进行优先排序。结果发表在BMC MEDICINE杂志上。

训练数据集包括9327名LDL-C浓度<70 mg/dL、无心血管疾病且未使用调脂药物的开滦一期研究人员(N = 101510)。在第二个中国队列中检查了该算法的有效性,该队列包括开滦二期研究中1753名LDL-C浓度<70 mg/dL的参与者(N = 35856)。

结果显示,在平均8.5-9.0年的随访期间,研究人员在训练数据集中发现388例缺血性卒中和145例出血性卒中,在验证数据集中发现20例缺血性卒中和8例出血性卒中。在15个检查的预测因子中,血压控制不佳和LDL-C浓度很低(≤40 mg/dL)是缺血性卒中风险和出血性卒中风险的最高层次预测因子。

相对于最低风险组(存在这些因素的0-1)的患者,存在2-3个上述风险因素为特征的群体与较高的缺血性卒中风险有关(训练集HR=7.03;95%CI 5.01-9.85;验证集HR=4.68,95%CI 1. 58-13.9)和出血性卒中(训练集HR=3.94,95%CI 2.54-6.11;验证集HR=4.73,95%CI 0.81-27.6)。累积平均LDL-C浓度与卒中风险之间存在线性关系。调整年龄、高血压状态和其他协变量后,与LDL-C浓度为55-70 mg/dL相比,LDL-C浓度≤40 mg/dL与缺血性卒中(HR= 2.07, 95%CI 1.53, 2.80)和出血性卒中(HR= 2.70, 95%CI 1.70, 4.30)风险增加明显相关。

综上,低密度脂蛋白胆固醇浓度极低的人,如果以前没有进行调脂治疗,仍可能有高的卒中风险。

 

参考文献:

The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations < 70 mg/dL. BMC Med 19, 142 (2021).

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 zhwj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1975209, encodeId=7f1b19e5209f5, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sat Sep 17 12:35:16 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281402, encodeId=050e1281402d9, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422618, encodeId=2560142261879, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611651, encodeId=8b85161165182, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623623, encodeId=0f67162362322, content=<a href='/topic/show?id=16fc9204535' target=_blank style='color:#2F92EE;'>#调脂治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92045, encryptionId=16fc9204535, topicName=调脂治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc220567061, createdName=muzishouyi, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626408, encodeId=62ae1626408f2, content=<a href='/topic/show?id=d71f9204488' target=_blank style='color:#2F92EE;'>#调脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92044, encryptionId=d71f9204488, topicName=调脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9fe521012482, createdName=gostraight, createdTime=Mon Jul 11 04:35:16 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 gostraight

相关资讯

Stroke:如何对短暂性脑缺血发作或小中风后进行多模式预防

强化护理项目组的患者在1年后体能和mRS的结果略好,但其他以患者为中心的结果都没有明显改善。

降压、降脂,防国人心血管病意义最大!周脉耕、胡国清等预测研究

血压控制对缺血性心脏病和出血性脑卒中死亡的贡献最大,分别可减少67.73和39.11万例的死亡。

Stroke:为第二次攻击做准备——关于中风后网络恢复能力的病变模拟研究

在这个经过高度筛选的病变局限于初级运动皮层的患者群中,大脑网络重新配置,以增加对未来打击事件的复原力。

JAMA:无症状严重颈动脉狭窄患者的缺血性中风发生率有多高?

无症状严重颈动脉狭窄患者队列中,没有进行手术干预,同侧颈动脉相关急性缺血性卒中的估计比率在5年内为4.7%。

stroke:≥85岁急性缺血性脑卒中患者血管内治疗后的功能结果

与保守治疗相比,≥85岁的独立病前功能患者在接受EVT治疗时更多地获得良好的功能结果,死亡率也更低。

拓展阅读

Cardiovasc Diabetol:不同体重指数和LDL-C水平的ACS患者中AIP与未诊断糖尿病的关系

急性冠脉综合征患者中,尤其是体重正常或LDL-C水平≥1.8 mmol/L的患者中,AIP与未诊断糖尿病的发生率显著相关。

“坏胆固醇”水平降低超60%!新型口服降脂药,12周疗效显著

一项2期研究,旨在评估3剂NNC0385-0434的安全性和降低LDL-C水平的效果。

新型长效降脂疗法,一次给药管半年!2024年共识:6条建议助力临床实践

2024年《小干扰RNA降脂药物药学专家共识》围绕siRNA降脂药物(以inclisiran为代表),对相关临床证据、药物安全性等进行了阐述。

这个年龄段的人适度吃他汀,便可显著改善“坏胆固醇”水平

与年轻人相比,低至中等强度他汀类药物治疗与老年人LDL-C水平的降幅更大相关。

瑞金医院研究:“坏胆固醇”不仅有害血管,还增加糖尿病风险,40岁以上要特别注意!

近日,Journal of Diabetes发表一项中国研究,表明在社区一般人群中,较高的LDL-C水平与糖尿病发病风险升高呈线性相关。

急性脑梗,最适LDL-C多高?天坛医院团队研究

研究表明,对于急性缺血性脑卒中(脑梗死)患者来说,当LDL-C为2.67 mmol/L时,死亡风险最低。